Marksans Pharma is pushing deeper into the US and other richer countries where demand for lower-cost medicines is growing, and it’s expanding factories to ship more products at better profit per sale. But heavy reliance on a few key markets and products leaves it exposed if competitors cut prices or regulators tighten the rules.Read more
Marksans Pharma is pushing deeper into tightly regulated overseas markets while ramping up new product launches and making better use of its underused factories, which could lift profits without a big spending jump. The key watch-outs are tough price competition in the U.S., delays in getting products approved, and the risk of an expensive acquisition that fails to pay off.Read more
Marksans Pharma is leaning more heavily on North America while also pushing a very crowded wave of new product filings across several countries, and that mix could squeeze profits if pricing gets tougher. See why its big growth plans could strain spending and supply chains, even as the company tries to use its unused factory capacity to expand.Read more
No trending discussion available.
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
